Phase I/II, Multicenter, Single-Arm Clinical Trial of Panitumumab in Combination with Cisplatin, Fluourouracil and Docetaxel (DCF) in Locally Advanced or Metastatic Cancer of the Stomach and Gastro-oesophageal junction

Trial Profile

Phase I/II, Multicenter, Single-Arm Clinical Trial of Panitumumab in Combination with Cisplatin, Fluourouracil and Docetaxel (DCF) in Locally Advanced or Metastatic Cancer of the Stomach and Gastro-oesophageal junction

Completed
Phase of Trial: Phase I/II

Latest Information Update: 02 May 2016

At a glance

  • Drugs Panitumumab (Primary) ; Cisplatin; Docetaxel; Fluorouracil; Pazopanib
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Apr 2016 Status changed from discontinued to completed.
    • 07 Oct 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 29 Oct 2012 Planned end date 1 Jul 2014 added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top